Log In
Print this Print this

paliperidone palmitate (3-month Invega Sustenna)

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionIntramuscular injection of paliperidone, a metabolite of risperidone, given once every 3 months
Molecular Target Monoamine receptors
Mechanism of ActionMonoaminergic receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationSchizophrenia
Indication DetailsTreat schizophrenia
Regulatory Designation U.S. - Priority Review (Treat schizophrenia)
PartnerAlkermes plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today